Destabilization of Abnormal Methylation Enzymes to Combat Cancer

Ming C. Liau

ISBN 10: 620266889X / ISBN 13: 9786202668897

Edité par LAP LAMBERT Academic Publishing Jun 2020, 2020

A propos de cet article

Neuware -The therapeutic end point of destabilization of abnormal methylation enzymes is terminally differentiated cells. This end point is compatible with the end point on the therapy of hematological cancers. It can fit in on the therapy of hematological cancers, but it will not be easy for the acceptance on the therapy of solid cancers. In combination with surgery, or cytotoxic chemotherapy to pursue the end point of tumor disappearance is perhaps an easy way out. Different end points, however, have to be sought to legitimate differentiation therapy. End point of the disappearance of circulating cancer stem cells, or restoration of plasma/urine peptide ratios to those of healthy people are valid, but need careful studies before being accepted as valid end points.Books on Demand GmbH, Überseering 33, 22297 Hamburg 60 pp. Englisch.

N° de réf. du vendeur 9786202668897

Détails bibliographiques

• Titre: Destabilization of Abnormal Methylation Enzymes to Combat Cancer
• Éditeur: LAP LAMBERT Academic Publishing Jun 2020
• Date de parution: 2020
• Langue: anglais
• ISBN à 10 chiffres: 620266889X
• ISBN à 13 chiffres: 9786202668897
• Reliure: Taschenbuch
• État de l'article: Neu
• Dimensions: 220 L x 150 H x 4 P (en millimètres) 220 millimètres de largeur par 150 millimètres de hauteur par 4 millimètres de profondeur
• Poids: 107 grammes

A propos de ce titre

Synopsis

The therapeutic end point of destabilization of abnormal methylation enzymes is terminally differentiated cells. This end point is compatible with the end point on the therapy of hematological cancers. It can fit in on the therapy of hematological cancers, but it will not be easy for the acceptance on the therapy of solid cancers. In combination with surgery, or cytotoxic chemotherapy to pursue the end point of tumor disappearance is perhaps an easy way out. Different end points, however, have to be sought to legitimate differentiation therapy. End point of the disappearance of circulating cancer stem cells, or restoration of plasma/urine peptide ratios to those of healthy people are valid, but need careful studies before being accepted as valid end points.